Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147251 | 0.78 | GRIA1 (0.40) | GRIA1 | |
| SCHEMBL25512413 | 0.75 | — | — | |
| SCHEMBL23872683 | 0.75 | GRIA1 (0.39) | GRIA1 | |
| SCHEMBL25927499 | 0.75 | GRIA1 (0.39) | GRIA1 | |
| SCHEMBL23278200 | 0.75 | — | — | |
| SCHEMBL24261144 | 0.75 | GRIA1 (0.39) | GRIA1 | |
| SCHEMBL25762154 | 0.75 | CA12 (0.30) | — | |
| SCHEMBL26144757 | 0.75 | GRIA1 (0.39) | GRIA1 | |
| SCHEMBL8277105 | 0.73 | GRIA1 (0.37) | GRIA1 | |
| SCHEMBL246741 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567232-A | Extraction separation method of alkyl benzothiophene in beta-methylnaphthalene | 中煤科工清洁能源股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117567232-A | Extraction separation method of alkyl benzothiophene in beta-methylnaphthalene | 中煤科工清洁能源股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230381180-A1 | SMALL MOLECULE MODULATORS OF KSR-BOUND MEK | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-11-30 | — | — | US | disclosed |
| US-20230381180-A1 | SMALL MOLECULE MODULATORS OF KSR-BOUND MEK | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-11-30 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-1130391-A | Dye mixtures containing azo dyes having the same colour and coupling component from diaminopyridine series | BASF AG (DE) | 1996-09-04 | — | — | CN | disclosed |
| CN-1092098-A | Aniline as markers for mineral oils | BASF AG (DE) | 1994-09-14 | — | — | CN | disclosed |
| US-5318969-A | Hypotensive, vasodilating action and muscle relaxants | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0339562-B1 | BENZOPYRAN COMPOUND AND ITS PHARMACEUTICAL USE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5143936-A | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| US-5021432-A | Hypotensive agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0339562-A1 | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4626537-A | Guanidines, pharmaceutical compositions and use | CIBA-GEIGY CORPORATION (US) | 1986-12-02 | — | — | US | disclosed |
| EP-0020303-B1 | GUANIDINES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS AND THEIR APPLICATION | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | disclosed |
| EP-0020303-A1 | Guanidines, process for their preparation, pharmaceutical preparations containing such compounds and their application | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | GRIA1 3210/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | GRIA1 1574/4885 |
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | RNGTT, RNMT, DNPEP | GRIA1 3499/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | GRIA1 2452/4885 |
| US-20230381180-A1 | SMALL MOLECULE MODULATORS OF KSR-BOUND MEK | KSR1, KSR2, BRAF | GRIA1 3116/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | GRIA1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.